MARKET

RPTX

RPTX

Repare Therapeutics Inc.
NASDAQ
3.580
+0.230
+6.87%
Closed 19:50 11/01 EDT
OPEN
3.380
PREV CLOSE
3.350
HIGH
3.600
LOW
3.340
VOLUME
42.93K
TURNOVER
0
52 WEEK HIGH
8.49
52 WEEK LOW
2.710
MARKET CAP
151.96M
P/E (TTM)
0.0000
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at RPTX last week (1028-1101)?
Weekly Report · 1d ago
Weekly Report: what happened at RPTX last week (1021-1025)?
Weekly Report · 10/28 09:17
Repare Therapeutics Price Target Maintained With a $10.00/Share by HC Wainwright & Co.
Dow Jones · 10/24 19:25
HC Wainwright & Co. Reiterates Buy on Repare Therapeutics, Maintains $10 Price Target
Benzinga · 10/24 19:16
Repare Therapeutics Receives Buy Rating Due to Improved Treatment Tolerability and Promising Clinical Outcomes
TipRanks · 10/24 15:25
TD Cowen Sticks to Its Buy Rating for Repare Therapeutics (RPTX)
TipRanks · 10/24 11:41
Repare Therapeutics presents data from Phase 1 MYTHIC clinical trial
TipRanks · 10/23 10:16
Repare Therapeutics Presented Updated Data Highlighting The Benefits Of Its Individualized Schedule For Managing Anemia In Phase 1 MYTHIC Trial, Which Treated Patients With The Combination Of Lunresertib And Camonsertib
Benzinga · 10/23 10:07
More
About RPTX
Repare Therapeutics Inc. is a clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Its pipeline includes lunresertib (RP-6306), a PKMYT1 inhibitor in Phase 1/2 clinical development; camonsertib (RP-3500), a potential Ataxia-Telangiectasia and Rad3-related protein kinase (ATR) inhibitor in Phase 1/2 clinical development; RP-1664, a Phase 1 PLK4 inhibitor; RP-3467, a preclinical polymerase theta adenosinetriphosphatase (ATPase) inhibitor program, and additional, undisclosed preclinical programs. RP-3500 is a potent and selective oral small molecule inhibitor of ATR in clinical development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations.

Webull offers Repare Therapeutics Inc stock information, including NASDAQ: RPTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RPTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RPTX stock methods without spending real money on the virtual paper trading platform.